Insud Pharma successfully closes acquisition deal for Women’s Healthcare business from Viatris

Madrid, 12 March 2024

  • Thanks to this deal the Spanish global company highlights its continuous commitment to women’s health and strengthens presence in emerging markets
  • The company adds two more plants to its manufacturing network

Insud Pharma today announced that it has completed the transaction to acquire the Women’s Healthcare business, primarily related to oral and injectable contraceptives, from Viatris. The transaction was first announced in October 2023.

Contraception and Women’s Healthcare represents a large and growing opportunity for emerging countries. Viatris supplies oral contraceptives to global institutions and this agreement will allow Insud Pharma to establish a position in these emerging markets and works closely with public health institutions.

This acquisition consolidates Insud Pharma's industrial presence in India with two additional manufacturing sites (Sarigam and Ahmedabad).

Lucas Sigman, Insud Pharma Chief Executive Officer, said “This transaction is a very important acquisition in the history of the company and highlights our continuous commitment to women’s health, and more than that, since it connects directly with the responsibility we share with our Mundo Sano foundation for health in emerging countries.

We are very happy to integrate two new sites in India and welcome a talented team. These two new facilities complete our network of plants in India together with Exeltis India (in Chennai) and Chemo India Formulations (in Hyderabad), having a total of more than 1,600 employees.”


Press contact

Communication Department
Edificio Ebrosa - Manuel Pombo Angulo, 28 3ª planta
28050 Madrid, España

Tel: +34 91 771 15 00